Status:
COMPLETED
A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD in Cystic Fibrosis Patients With at Least 1 G542X Allele
Lead Sponsor:
Eloxx Pharmaceuticals, Inc.
Conditions:
Cystic Fibrosis
Eligibility:
All Genders
16+ years
Phase:
PHASE2
Brief Summary
This is a Phase 2 open label study to evaluate the safety, tolerability, PK, and PD of multiple dose levels of SC administered ELX-02 with and without ivacaftor in patients with CF with at least one G...
Eligibility Criteria
Inclusion
- Patients must meet the following criteria to participate in this study:
- Males and females age 18 years and above in Germany and Israel; in countries where permitted, males and females age 16 years and above
- A confirmed diagnosis of nmCF with a documented G542X or phenotypically similar nonsense mutation, homozygote, or compound heterozygote with one of the specified mutations. For heterozygotes, one mutation has to be G542X or phenotypically similar nonsense mutation, and the second mutation could be and Class 1 or Class 2 mutation. Patients with one G542X or phenotypically similar nonsense allele and a second allele that is not in the above list may be potentially allowed but only after discussion on a case by case basis with and written approval from the Sponsor.
- Documented SCC ≥ 60 mEq/L
- FEV1 ≥ 40% predicted normal for age, gender and height at Screening (Knudson Equation)
- Body Mass Index (BMI) of 19.0 to 30.0 kg/m2 (inclusive).
- Patients with any of the following characteristics/conditions will not be included in the study:
- Participation in clinical study including administration of any investigational drug or device in the last 30 days or 5 half-lives (whichever is longer) prior to investigational product dosing in the current study
- History of any organ transplantation
- Major surgery within 180 days (6 months) of Screening
- Patients without documented prior aminoglycoside exposure who have a mitochondrial mutation that has been shown to increase sensitivity to aminoglycosides
- Known allergy to any aminoglycoside
- Patients with any abnormality at ENT screening, that indicates the presence of a vestibular toxicity associated with prior exposure to aminoglycosides.
- Dizziness Handicap Inventory (DHI)-H score at screening \>16
- Patients receiving CFTR modulators within 2 months of study treatment
Exclusion
Key Trial Info
Start Date :
November 5 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 6 2022
Estimated Enrollment :
17 Patients enrolled
Trial Details
Trial ID
NCT04126473
Start Date
November 5 2019
End Date
April 6 2022
Last Update
August 21 2023
Active Locations (9)
Enter a location and click search to find clinical trials sorted by distance.
1
The Royal Prince Alfred Hospital
Camperdown, New South Whales, Australia, 2050
2
The Royal Adelaide Hospital
Adelaide, South Australia, Australia
3
The Alfred Hospital
Melbourne, Victoria, Australia
4
Universitätsmedizin Essen Ruhrlandklinik
Essen, North Rhine-Westphalia, Germany, 45239